Drugs & Aging

, Volume 29, Issue 12, pp 941–947

The Pharmacological Management of Post-Stroke Muscle Spasticity

Therapy in Practice


Muscle hypertonia following upper motor neurone lesions (referred to here as ‘spasticity’) is a common problem in patients with neurological disease, and its management is one of the major challenges in clinical practice. Understanding the pathogenesis and clinical course of spasticity is essential for the effective management of this condition. The hypertonia initially results from increased excitability of the alpha motor neurones due to an imbalance between the excitatory and inhibitory influences of the vestibulospinal and reticulospinal tracts. This is the ‘neural component’ of muscle hypertonia. However, usually within 3–4 weeks, changes in the structure and mechanical properties of the paralysed muscles and the effect of thixotropy also contribute to the hypertonia. The selection of the optimal treatment option is often influenced by whether the neural or the non-neural component is more pronounced. Muscle spasticity often interferes with motor function or causes distressing symptoms, such as painful muscle spasms. If untreated, spasticity may also lead to soft tissue shortening (fixed contractures). However, spasticity can also be beneficial to patients. For example, despite severe leg muscle weakness, most hemiplegic patients are able to walk because the spasticity of the extensor muscles braces the lower limb in a rigid pillar. Other reported benefits of spasticity include the maintenance of muscle bulk and bone mineral density and possibly a reduced risk of lower limb deep vein thrombosis. Several factors, such as skin pressure sores, faecal impaction, urinary tract infections and stones in the urinary bladder, can aggravate muscle spasticity. These factors should always be looked for as their adequate treatment is often sufficient to reduce muscle tone without the need for specific antispasticity medication. Therefore, a careful evaluation of the patient’s symptoms and their impact on function, and the setting of clear and realistic therapy goals are important prerequisites to treatment. The best treatment outcomes are usually achieved when pharmacological and non-pharmacological treatment modalities are used in tandem. Different drugs are available for the management of spasticity, including oral muscle relaxants, anticonvulsant drugs, intrathecal baclofen, cannabis extract, phenol and alcohol (for peripheral nerve blocks) and botulinum toxin injections. Similarly, there is a range of non-pharmacological methods of treatment, e.g. regular muscle stretching, the use of splints and orthoses, electrical stimulation, etc. Although these are not discussed here, this should not detract from the importance of combining them with antispasticity drugs in order to maximize the clinical benefit of treatment.


  1. 1.
    Wissel J, Schelosky LD, Scott J, Christe W, Faiss JH, Mueller J. Early development of spasticity following stroke: a prospective, observational trial. J Neurol. 2010;257:1067–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. Clin Rehabil. 2002;16:515–22.PubMedCrossRefGoogle Scholar
  3. 3.
    Lundström E, Smits A, Borg J, Terént A. Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity—the first year after the event. Stroke. 2010;41:319–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chicago: Year Book Medical Publishers; 1980. p. 485–94.Google Scholar
  5. 5.
    Alexon WH. Signs of muscle thixotropy during human ballistic wrist joint movements. J Appl Physiol. 2005;99:1922–9.CrossRefGoogle Scholar
  6. 6.
    Bakheit AMO, Fheodoroff K, Molteni F. Spasticity or reversible hypertonia? J Rehabil Med. 2011;43:556–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Royal College of Physicians of London, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. Spasticity in adults: management using botulinum toxin. National guidelines. London: Royal College of Physicians; 2009.Google Scholar
  8. 8.
    Dvir Z, Panturin E, Prop I. The effect of graded effort on the severity of associated reactions in hemiplegic patients. Clin Rehabil. 1996;10:155–8.CrossRefGoogle Scholar
  9. 9.
    Rushworth G. The nature and management of spasticity. Proc R Soc Med. 1964;57:29–34.Google Scholar
  10. 10.
    Bohannon RW, Smith MB. Inter-rater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67:206–7.PubMedGoogle Scholar
  11. 11.
    Tardieu G, Shentoub S, Delarue R. In search of a technique for measuring spasticity. Revue Neurolique. 1954;91:143–4.Google Scholar
  12. 12.
    Löfvenmark I, Werhagen L, Norrbrink C. Spasticity and bone density after a spinal cord injury. J Rehabil Med. 2009;41:1080–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Eser P, Frotzler A, Zehnder Y, et al. Assessment of anthropometric, systemic, and lifestyle factors influencing bone status in the legs of spinals cord injured individuals. Osteoporos Int. 2005;16:26–34.PubMedCrossRefGoogle Scholar
  14. 14.
    Warlow C, Ogston D, Douglas AS. Deep venous thrombosis of the legs after strokes. Part I—incidence and predisposing factors. Br Med J. 1976;1:1178–83.PubMedCrossRefGoogle Scholar
  15. 15.
    Ward AB, Aquilar M, De Beyl Z, et al. Use of botulinum toxin type A in management of adult spasticity—a European consensus statement. J Rehabil Med. 2003;35:98–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Yelnik AP, Simon O, Bensmail D, Chaleat-Valayer E, Decq P, Dehail P, Quentin V, Marque P, Parratte B, Pellas F, Rousseaux M, Trocello J-M, Uzzan M, Dumarcet N. Drug treatments for spasticity. Ann Phys Rehabil Med. 2009;52:746–56.PubMedCrossRefGoogle Scholar
  17. 17.
    Pedersen E, Arlien-Søborg P, Mai J. The mode of action of the GABA derivative baclofen in human spasticity. Acta Neurol Scand. 1974;50:665–80.PubMedCrossRefGoogle Scholar
  18. 18.
    Coward DM. Tizanidine: neuropharmacology and mechanism of action. Neurology. 1994;44(Suppl 9):S6–10.PubMedGoogle Scholar
  19. 19.
    Morgan KG, Brayant SH. The mechanism of action of dantrolene sodium. J Pharmacol Exp Ther. 1977;201:138–47.PubMedGoogle Scholar
  20. 20.
    Nielsen JF, Hansen HJ, Sunde N, et al. Evidence of tolerance to baclofen in treatment of severe spasticity with intrathecal baclofen. Clin Neurol Neurosurg. 2002;104:142–5.PubMedCrossRefGoogle Scholar
  21. 21.
    The British Medical Association and The Royal Pharmaceutical Society of Great Britain. British National Formulary (March 2012). London: BMJ Group and Pharmaceutical Press; 2012.Google Scholar
  22. 22.
    Rose MA, Kam PCA. Gabapentin: pharmacology and its use in pain management. Anaesthesia. 2002;57:451–62.PubMedCrossRefGoogle Scholar
  23. 23.
    Bradley LJ, Kirker SG. Pregabalin in the treatment of spasticity: a retrospective case series. Disabil Rehabil. 2008;30:1230–2.PubMedCrossRefGoogle Scholar
  24. 24.
    Mueller ME, Gruenthal M, Olsen WL, et al. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil. 1997;78:521–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Gruenthal M, Mueller ME, Olsen WL, et al. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord. 1997;35:686–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Cutter NC, Scott DD, Johnson JC. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled randomized trial. Arch Phys Med Rehabil. 2000;81:164–9.PubMedGoogle Scholar
  27. 27.
    Simpson DM, Alexander DN, O’Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized double-blind placebo controlled trial. Neurology. 1996;46:1306–10.PubMedCrossRefGoogle Scholar
  28. 28.
    Bakheit AMO, Thilmann AF, Ward AB, et al. A randomized double-blind placebo-controlled dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb muscle spasticity after stroke. Stroke. 2000;31:2402–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Bakheit AMO, Pittock S, Moore AP, et al. A randomized double-blind placebo-controlled study of the efficacy and safety of botulinum toxin type A (Dysport) in upper limb muscle spasticity in patients with stroke. J Neurol. 2001;8:559–65.Google Scholar
  30. 30.
    Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. N Engl J Med. 2002;347:395–400.PubMedCrossRefGoogle Scholar
  31. 31.
    van Campenhout A, Molenaers G. Localization of the motor endplate zone in human skeletal muscles of the lower limb: anatomical guidelines for injection with botulinum toxin. Dev Med Child Neurol. 2011;53:108–19.PubMedCrossRefGoogle Scholar
  32. 32.
    Gracies JM, Lugassy M, Weisz DJ, Vecchio M, Flanagan S, Simpson DM. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil. 2009;90:9–16.PubMedCrossRefGoogle Scholar
  33. 33.
    Durif F. Clinical bioequivalence of the current commercial preparations of botulinum toxin. Eur J Neurol. 1995;2:17–8.Google Scholar
  34. 34.
    Odergren T, Hjaltasaon H, Kaakkola S, Solders G, Hanko J, Fehling C, et al. A double blind, randomised, parallel group study to investigate the dose of equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64:6–12.PubMedCrossRefGoogle Scholar
  35. 35.
    Roggenkamper P, Jost WH, Bihari K, et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303–12.PubMedCrossRefGoogle Scholar
  36. 36.
    Blitzer A. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. Otolaryngol Head Neck Surg. 2005;133:836–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Bakheit AMO, Ward CD, McLellan DL. Generalised botulism-like syndrome following intramuscular injections of botulinum toxin type A—a report of two cases. J Neurol Neurosurg Psychiatry. 1997;62:198.PubMedCrossRefGoogle Scholar
  38. 38.
    Hatheway CH, Dang C. Immunogenicity of the neurotoxins of clostridium botulinum. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. p. 93–107.Google Scholar
  39. 39.
    Bakheit AMO, Liptrot A, Newoton R, et al. The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity. Int J Rehabil Res. 2012;35:36–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Zajicek J, Fox P, Sanders H, et al. Cannabinoids for the treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362:1517–26.PubMedCrossRefGoogle Scholar
  41. 41.
    Bakheit AMO, Badwan DAH, McLellan DL. The effectiveness of chemical neurolysis in the treatment of lower limb muscle spasticity. Clin Rehabil. 1996;10:41–4.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2012

Authors and Affiliations

  1. 1.Inpatient Neurological Rehabilitation UnitMoseley Hall HospitalBirminghamUK

Personalised recommendations